-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Latest From Biotech Now
Boosting Investment in Biotech
The President’s Council on Jobs and Competitiveness issued an interim report with suggestions to increase job creation and growth in the U.S., as well as plans for encouraging investment in the industry. Of particular interest to the biotech industry, the report offers suggestions for streamlining the FDA approval process. The report also outlines ideas for eliminating capital gains on investments of $25 million or less that are held for at least five years and recommends Read More >
BIO’s New Personalized Medicine and Diagnostics Working Group
The Biotechnology Industry Organization (BIO) represents a diverse portfolio of companies throughout the continuum of personalized medicine. These companies include those that develop therapeutic and diagnostic products, as well as research tools companies that drive innovation in this area. With broad member representation from across the drug, biologic, diagnostic and research tool industries, BIO is uniquely positioned to serve as industry’s key voice on personalized medicine issues. As part of an effort to better utilize Read More >
Biotechnology Delivers Medical Discoveries to Benefit Women Facing Breast Cancer
By Marc S. Hurlbert, Ph.D., Executive Director, Avon Foundation Breast Cancer Crusade The field of breast cancer has witnessed remarkable progress due to dedicated biotechnology and academic scientists, advocates, patients, nurses and physicians. Sixty years ago, a woman diagnosed with early stage breast cancer had less than a 55 percent chance of living 10 years, while today those odds are greater than 85 percent. We have made great advances in detecting cancer early with imaging including Read More >
Increasing Partnering at BIO
Mike May from Biotech Tallies writes: At the 2011 BIO International Convention, the number of one-on-one partnering meetings soared to 21,183… The increasing number of such meetings probably reflects the growth in biotechnology, the escalating importance of BIO’s annual meeting and the expanding need to partner for success in this field.
If Politics Trumps Science, Businesses Will Leave the U.S.
The Anchorage Daily News ran an editorial authored by California Farmer and Alaska fisherman Ted Sheely about the still-pending approval of the genetically engineered salmon. Sheely says some politicians in Washington think they have identified a threat to the pristine Alaska wilderness. These members of Congress are trying to force the federal government to slow down or stop a technology company that has figured out a way to make salmon less expensive for ordinary consumers. If they Read More >
